Experiences and outcomes after Rectal Cancer Treatment with total neoadjuvant therapy.
Summary
We want to understand patient's experiences, perspectives and preference with locally advanced rectal cancer treatment in Alberta. Our study looks at patients with locally advanced rectal cancer (stage II/III), who are often treated first with chemotherapy and radiation, in what is called "total neoadjuvant treatment" or "TNT".
After TNT patients either receive surgery, or select patients undergo a non operative "watch and wait" strategy. Many regimens of chemoradiation exist. Our study looks at the outcomes of the different regiments both from a cancer perspective, as well as a quality of life perspective. We want to know from patients how their experience was, and what their priorities and perceptions are. Furthermore, we want to understand how the treatment impacts their bowel function and quality of life.
This study aims to create a database of patients with rectal cancer who have undergone TNT in Alberta. We are also providing an optional survey for patients at 1-year and 2-years post treatment, to be able to provide the patient perspective on their treatment experience.
Eligibility
Eligible ages: 18 to 100
Inclusion criteria:
1. New diagnosis of rectal cancer undergoing chemotherapy and radiation
2. Plan for surgery or watch and wait approach after chemotherapy and radiation.
3. At least age 18
Exclusion criteria:
You are not eligible to participate if you do not live in Alberta or if you are under the age of 18.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Christine Wang
Principal investigator:
Tamara Gimon
Clinical trial:
No
REB-ID:
HREBA.CC-23-0272